These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32009788)

  • 1. Profile Of Patients With Advanced Parkinson's disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients.
    Szász JA; Constantin VA; Orbán-Kis K; Rácz A; Bancu LA; Georgescu D; Szederjesi J; Mihály I; Fárr AM; Kelemen K; Vajda T; Szatmári S
    Neuropsychiatr Dis Treat; 2019; 15():3187-3195. PubMed ID: 32009788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics of levodopa treatment in advanced Parkinson's disease in the experiences of the neurology clinics of Târgu Mureș, Romania].
    Szász JA; Szatmári S; Constantin V; Mihály I; Rácz A; Domokos LC; Vajda T; Orbán-Kis K
    Orv Hetil; 2019 Apr; 160(17):662-669. PubMed ID: 31010306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Parkinson's Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis.
    Simu MA; Jianu DC; Dulamea AO; Constantin VA; Popescu D; Parra JC; Szász JA
    Brain Sci; 2021 Nov; 11(12):. PubMed ID: 34942868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
    Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA
    Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson's Disease.
    Szász JA; Constantin VA; Orbán-Kis K; Bancu LA; Ciorba M; Mihály I; Nagy EE; Szász RM; Kelemen K; Simu MA; Szatmári S
    Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34206596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Observations and Dilemmas after 10 Years of Real-Life Experience.
    Szász JA; Constantin VA; Orbán-Kis K; Bancu LA; Bataga SM; Ciorba M; Nagy E; Neagoe MR; Mihály I; Szász RM; Kelemen K; Simu M; Szatmári S
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors.
    Metta V; Batzu L; Leta V; Trivedi D; Powdleska A; Mridula KR; Kukle P; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching and Combining Device-Aided Therapies in Advanced Parkinson's Disease: A Double Centre Retrospective Study.
    Georgiev D; Delalić S; Zupančič Križnar N; Socher A; Gurevich T; Trošt M
    Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body image appearance in Parkinson's disease patients on device aided therapies.
    Proietti F; Pontani M; Pepe A; Magliozzi A; Toro S; Anzini G; Albergo G; Ricciuti R; Di Lazzaro V; Marano M
    Neurol Sci; 2024 Sep; ():. PubMed ID: 39269573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria for identification of advanced Parkinson's disease: the results of the Italian subgroup of OBSERVE-PD observational study.
    Stefani A; Tessitore A; Tambasco N; Cossu G; Ceravolo MG; Defazio G; Morgante F; Ramat S; Melzi G; Gualberti G; Merolla R; Onuk K; Lopiano L
    BMC Neurol; 2022 Jan; 22(1):41. PubMed ID: 35090406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
    Fasano A; Gurevich T; Jech R; Kovács N; Svenningsson P; Szász J; Parra JC; Bergmann L; Johnson A; Sanchez-Soliño O; Tang Z; Vela-Desojo L
    Mov Disord; 2021 Aug; 36(8):1853-1862. PubMed ID: 33908647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life assessment when considering the introduction of device-assisted therapies in advanced Parkinson's disease: A retrospective observational cross-sectional study.
    Ueno T; Haga R; Arai A; Tomiyama M
    J Neurol Sci; 2024 Feb; 457():122890. PubMed ID: 38232467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
    Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
    J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Device-Aided Therapies in Parkinson's Disease-Results from the German Care4PD Study.
    Fründt O; Hanff AM; Möhl A; Mai T; Kirchner C; Amouzandeh A; Buhmann C; Krüger R; Südmeyer M
    Brain Sci; 2023 Apr; 13(5):. PubMed ID: 37239208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of advanced Parkinson's disease: OBSERVE-PD observational study - results of the Swiss subgroup.
    Möller JC; Baumann CR; Burkhard PR; Kaelin-Lang A; Küng I; Onuk K; Bohlhalter S
    Swiss Med Wkly; 2021 Mar; 151():w20419. PubMed ID: 33705561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
    Antonini A; Poewe W; Chaudhuri KR; Jech R; Pickut B; Pirtošek Z; Szasz J; Valldeoriola F; Winkler C; Bergmann L; Yegin A; Onuk K; Barch D; Odin P;
    Parkinsonism Relat Disord; 2017 Dec; 45():13-20. PubMed ID: 29037498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.